Posted on

cbd and circulation

Cbd and circulation

While buying a CBD product, make certain that it is organic and contains less than 0.3 % THC. If the THC level in the product exceeds this limit, the product is not legal in the US. Also, the CBD product you buy should have a Certificate of Analysis.

This article was originally published on Free CBD Relief. To view the original article, click here.

Studies have shown that CBD oil has various beneficial effects on the body. It can help lessen inflammation alongside lowering chronic pain and improving the immune system. Additionally, it is can effectively treat countless other health conditions.

Buying CBD Products

In this article, we will take a look at how CBD can help in improving blood circulation in your body.

A study conducted in 2020 suggested that cannabinoids can improve a person’s blood flow. The study found that cannabinoids can cause blood vessels to widen. Another study held in 2017 showed that a single dosage of CBD oil reduced blood pressure.

The American Institute of Stress declared that stress can cause blood pressure to spike. This is because the hormones that cause blood pressure to increase can restrict the flow of blood to the body. CBD is proven to be effectual in minimizing stress.

You should be careful when choosing a vendor to buy CBD products. Many companies sell CBD products, but only a few of them sell high-quality CBD products. You can do an internet search or ask a friend who uses CBD products to know about the reputed CBD brands in the market.

CBD For Blood Circulation

Cbd and circulation

The acute vascular effects of cannabinoid compounds have been well studied in a range of models. In a variety of in vivo and in vitro models, phytocannabinoids and endogenous cannabinoids (endocannabinoids) have been shown to cause vasorelaxation. However, the potency, efficacy and mechanisms of action often differ. For example, early work in rabbit cerebral arteries showed that THC and the endocannabinoid anandamide (AEA) caused vasorelaxation that was dependent on cyclooxygenase (COX) activity [14]. Later, Randall et al. [15] showed AEA-induced vasorelaxation in the perfused rat mesenteric bed that was inhibited by antagonism of the CB1 receptor and inhibition of potassium hyperpolarization. The vasorelaxant effects of AEA in rat arteries are also dependent on the vessel size in that the maximal response to AEA is greater in small resistance vessels and includes an endothelial-dependent component that is not observed in larger arteries [16]. In rat aortae, the vasorelaxant response to AEA is not sensitive to CB1 antagonism or TRPV1 desensitization, but is sensitive to Gi/o protein inhibition using pertussis toxin (PTX) [17]. Further differences in cannabinoid effects can be found when comparing the same arterial bed of differing species. In rabbit aortae, AEA causes greater maximal relaxation than observed in rat aortae through a SR141716A (1 µ m ) sensitive pathway which is dependent on the endothelium [18]. It has also been shown that cannabinoid responses are dependent on the cannabinoid compound used. For example, the endocannabinoids AEA and N-arachidonoyl-dopamine (NADA) cause similar degrees of vasorelaxation in rat aortae, but by different mechanisms [17]. These studies highlight the complexity of acute vasodilator actions of cannabinoids on the vasculature (for a full review see [19]).

Vascular effects of cannabinoids

Fewer studies have investigated the vascular effects of CBD. Jarai and colleagues [25] found no effect of perfusing 10 µM CBD on vascular tone in phenylephrine-constricted rat mesenteric vascular bed. However, in arterial segments taken from the rat mesenteric vascular bed that have been mounted onto a Mulvany-Halpern myograph and constricted with phenylephrine, CBD causes a concentration-dependent near-maximal vasorelaxation [28]. Unfortunately, this study did not probe the mechanisms underlying this vasorelaxant effect of CBD in rat mesenteric arteries.

Direct vascular effects of CBD

As previously discussed, administration of CBD (3 mg kg −1 i.v.) at the same time as LPS maintains BBB integrity [34]. Although CBF was not measured directly, the results observed from various parameters led the authors to suggest that CBD had ameliorated the LPS-induced drop in CBF [34]. BBB disruption is an important facet in the pathophysiology of ischaemic stroke [73]. Therefore, CBD-mediated preservation of this barrier, as demonstrated in other disease models could represent another mechanism of CBD-mediated protection in ischaemic stroke. Agonism of PPARγ may represent another mechanism of action for the beneficial effects of CBD in stroke. Several groups have found that synthetic PPARγ agonists, thiazolidinediones (TZDs), a class of drugs used to improve insulin sensitivity, reduced infarct size and improved functional recovery from stroke in rats [74–78]. Improvement is associated with reduced inflammation which is a probable mechanism of recovery, and, importantly, improvement is seen whether TZDs are administered before or after MCAO [75, 77]. Recently, in vivo CBD treatment has been shown to have neuroprotective effects in an Alzheimer’s disease model which were inhibited with a PPARγ antagonist [6]. Similarly, we have shown in a cell culture model of the BBB that CBD restores the enhanced permeability induced by oxygen glucose deprivation, which could be inhibited by a PPARγ antagonist (Hind & O’Sullivan, unpublished observations).